Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
![GlobeNewswire](../../../Content/images/providers/GN.png)
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: GlobeNewswire
WARRINGTON, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced an update of istaroxime in both clinical and business development. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in three positive Phase 2 trials enrolling patients with acute heart failure (AHF) and early cardiogenic shock. In line with previous guidance, the Company expects its Phase 2 SEISMiC Extension Study in SCAI Stage B early cardiogenic shock patients to complete enrollment in the next several weeks and report topline data by the end of this quarter. Building upon the positive SEISMiC study results, the Extension Study
Show less
Read more
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockGlobeNewswire
- Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business UpdatesGlobeNewswire
- Windtree Announces New Additions and Changes to Its Board of DirectorsGlobeNewswire
- Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock [Yahoo! Finance]Yahoo! Finance
- Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred StockGlobeNewswire
WINT
Sec Filings
- 9/4/24 - Form EFFECT
- 9/4/24 - Form EFFECT
- 9/3/24 - Form 424B5
- WINT's page on the SEC website